Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2CNS 2

Conditions

Melanoma 34Neoplasms 21Carcinoma, Non-Small-Cell Lung 7Brain Neoplasms 5Skin Neoplasms 4Neoplasm Metastasis 4Glioma 4Thyroid Carcinoma, Anaplastic 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Astrocytoma 2Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Multiple Myeloma 1Melanoma, Cutaneous Malignant 1Leukemia, Hairy Cell 1Gastrointestinal Stromal Tumors 1Fever 1

Interventions

trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Histiocytosis, Langerhans-Cell × dabrafenib × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Novartis

Phase 1/2 Completed
139 enrolled 42 charts 1 FDA
CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡